慢性低O_2高CO_2性肺动脉高压大鼠脑超微结构改变与MDA、SOD变化及培哚普利的治疗作用

目的 :探讨慢性低O2 高CO2 时神经元线粒体及髓鞘的改变与氧自由基的变化关系及培哚普利的治疗作用。方法 :采用慢性低O2 高CO2 肺动脉高压模型 ,应用培哚普利治疗 ,电镜观察大鼠脑超微结构并测定MDA和SOD。结果 :观察到脑血管内皮细胞锯齿状突起 ,管腔狭窄 ,神经元线粒体空泡变及髓鞘分层断裂 ,测得实验大鼠MDA升高 ,SOD降低 ,用药组大鼠脑血管和神经元结构损害明显减轻。结论 :提示慢性低O2 高CO2 时神经元线粒体及髓鞘改变与MDA升高有关 ,培哚普利对慢性低O2 高CO2 时脑损害有保护作用。     

Dietary n‐3 polyunsaturated fatty acids affect the development of renovascular hypertension in rats

The consequences of a dietary n3 PUFA supply was investigated on the blood pressure (BP) increase elicited by left renal artery stenosis in rats distributed in 3 groups (n = 8) fed for 8 weeks a semipurified diet either as control diet or enriched diets (docosahexaenoic acid, DHA, or eicosapentaenoic acid, EPA). The PUFA intake induced large alterations in heart and kidney phospholipid fatty acid profile, but did not influence body weight, cardiac hypertrophy, renal left atrophy and right hypertrophy. Within 4 weeks, BP raised from 120–180 ± 2 mm Hg in the control group, but only to 165 ± 3 mm Hg in the n3 PUFA groups. After stabilization of BP in the 3 groups, the rats received a short administration of increasing dose of perindopril. The lower dose (0.5 mg/kg) moderately decreased BP only in the control group. With higher doses (1, 5 and 10 mg/kg) BP was normalized in the 3 groups, with a higher amplitude of the BP lowering effect in the control group. A moderate n3 PUFA intake can contribute to prevent the development of peripheral hypertension in rats by a mechanism that may involve angiotensin converting enzyme.     

缬沙坦联合培哚普利对慢性心力衰竭患者心功能及血浆BNP、CRP、IL-6

目的：观察缬沙坦联合培哚普利对慢性-22力衰竭（CHF）的治疗效果,以及对患者心功能、血浆脑利钠肽（BNP）、c反应蛋白（CRP）和IL-6的影响。方法：95例CHF患者随机分为缬沙坦治疗组（30例）、培哚普利治疗组（30例）和联合治疗组（35例）,患者均予以常规西医治疗,缬沙坦治疗组或培哚普利治疗组在常规治疗基础上加用缬沙坦或培哚普利,联合治疗组则同时加用缬沙坦和培哚普利。观察治疗效果及患者心功能变化,检测治疗前后血浆BNP、CRP、IL-6的浓度。结果：联合治疗组总有效率达到91．43％,高于缬沙坦治疗组73．33％和培哚普利53．33％的总有效率（P〈0．05）;与缬沙坦治疗组和培哚普利治疗组相比,缬沙坦联合培哚普利可有效改善患者心功能指标,降低血浆BNP、CRP、IL-6含量。结论：缬沙坦联合培哚普利能有效改善心功能,调节细胞因子表达,优于单用缬沙坦或培哚普利治疗。     

Jian-Pi-Yi-Shen formula enhances perindopril inhibition of chronic kidney disease progression by activation of SIRT3, modulation of mitochondrial dynamics,and antioxidant effects

Chronic kidney disease (CKD) is a global public health problem. Renin–angiotensin system (RAS) blockade is the mainstay of CKD therapy with limitations. Jian-Pi-Yi-Shen formula (JPYSF) is a traditional herbal decoction and has been used for treating CKD for decades. The purpose of the present study was to investigate the intervention effects of combined used of perindopril erbumine (PE) and JPYSF on CKD progression and explore their underlying mechanisms. CKD rat model was induced by feeding a diet containing 0.75% w/w adenine for 3 weeks. CKD rats were treated with PE or JPYSF or PE+JPYSF from the induction of CKD and lasted 4 weeks. Renal function was evaluated by serum creatinine (Scr) and blood urea nitrogen (BUN). Pathological lesions were observed by Periodic acid–Schiff (PAS) and Masson’s trichrome staining. The protein expression was tested by Western blot and immunohistochemistry analysis. The morphology of mitochondria was observed by transmission electron microscope. The results showed that combined used of PE and JPYSF could better improve renal function and pathological lesions and ameliorate renal fibrosis in CKD rats. Administration of PE and JPYSF enhanced sirtuin 3 (SIRT3) expression, inhibited mitochondrial fission, promoted mitochondrial fusion, and suppressed oxidative stress in the kidney of CKD rats. In conclusion, combined use of PE and JPYSF protected against CKD more effectively than either alone. The underlying mechanism may be associated with activation of SIRT3, modulation of mitochondrial dynamics, and antioxidant effects.     

S‐perindopril assay using a potentiometric,enantioselective membrane electrode

A potentiometric, enantioselective membrane electrode based on graphite paste (graphite powder and paraffin oil) has been constructed. The graphite paste is impregnated with a 10⁻³ mol/L 2‐hydroxy‐3‐trimethylammoniopropyl‐β‐cyclodextrin (as chloride salt) solution. The potentiometric, enantioselective membrane electrode can be used reliably for enantiopurity tests of S‐perindopril using a chronopotentiometric (zero current) technique, in the 10⁻⁵–10⁻² mol/L concentration range (detection limit 5 × 10⁻⁶ mol/L), with an average recovery of 99.58% (RSD = 0.33%). The enantioselectivity was determined over R‐perindopril and d ‐proline. The response characteristics of the enantioselective, potentiometric membrane electrode were also determined for R‐perindopril. It was shown that l ‐proline is the main interfering compound. The surface of the electrode can be regenerated simply by polishing, obtaining a fresh surface ready to be used in a new assay. Chirality 11:631–634, 1999. © 1999 Wiley‐Liss, Inc.     

缬沙坦联合培哚普利对慢性心力衰竭患者心功能及血浆BNP、CRP、IL-6 的影响

目的:观察缬沙坦联合培哚普利对慢性心力衰竭(CHF)的治疗效果,以及对患者心功能、血浆脑利钠肽(BNP)、C反应蛋白(CRP)和IL-6的影响。方法:95例CHF患者随机分为缬沙坦治疗组(30例)、培哚普利治疗组(30例)和联合治疗组(35例),患者均予以常规西医治疗,缬沙坦治疗组或培哚普利治疗组在常规治疗基础上加用缬沙坦或培哚普利,联合治疗组则同时加用缬沙坦和培哚普利。观察治疗效果及患者心功能变化,检测治疗前后血浆BNP、CRP、IL-6的浓度。结果:联合治疗组总有效率达到91.43%,高于缬沙坦治疗组73.33%和培哚普利53.33%的总有效率(P<0.05);与缬沙坦治疗组和培哚普利治疗组相比,缬沙坦联合培哚普利可有效改善患者心功能指标,降低血浆BNP、CRP、IL-6含量。结论:缬沙坦联合培哚普利能有效改善心功能,调节细胞因子表达,优于单用缬沙坦或培哚普利治疗。     

Urinary zinc excretion is normalized in primary arterial hypertension after perindopril treatment

Increased or unchanged urinary zinc excretion has been reported in hypertension. In the present article, this observation was confirmed in a group of 10 untreated hypertensive patients of both sexes that had no diabetes or obesity. The 24-h zinc excretion was significantly different between the patients: 7.46±3.01 μmol and healthy controls: 5.19±2.19 μmol (p<0.025). After a 1-mo treatment with 4 mg perindopril per day, a decrease of urinary zinc was observed until it reached levels not significantly different from those of the healthy controls (5.98±2.13 μmol). The decrease was significantly different from that of the pretreatment values (p<0.05).     

A possible Fourier transform infrared‐based plasma fingerprint of angiotensin‐converting enzyme inhibitor‐induced reversal of endothelial dysfunction in diabetic mice

Angiotensin‐converting enzyme inhibitors (ACE‐I) display vasoprotective activity and represent the cornerstone in the treatment of cardiovascular diseases. In this study, we tested whether Fourier transform infrared (FTIR)‐based analysis of blood plasma is sensitive to detect vasoprotective effects of treatment with perindopril including reversal of endothelial dysfunction in diabetes. For this purpose, plasma samples were collected from untreated db/db mice, db/db mice treated with 2 or 10 mg/kg perindopril and db+ mice. The effect of perindopril on endothelial function was examined in ex vivo aortic rings; 10 mg/kg but not 2 mg/kg of perindopril reversed endothelial dysfunction. In plasma of db/db mice, the balance between conformations of plasma proteins was noted, and treatment with perindopril at a high dose but not at a low dose reversed this effect. This was revealed by amide II/amide I ratio attributed to increased β‐sheet formation. Spectral markers at 3010, 1520/1238 cm^?1, representative for unsaturation degree of lipids and phosphorylation of tyrosine, respectively, were also affected by perindopril treatment. In conclusion, although metabolic abnormalities associated with type 2 diabetes mellitus such as hypertriglyceridemia and hyperglycemia strongly affected spectral FTIR profile of diabetic plasma, we identified FTIR features that seem to be associated with the vasoprotective activity of ACE‐I.      

Utilization of erythrosine B in spectrofluorimetric quenching analysis of amlodipine and perindopril in pharmaceutical and biological matrices

A spectrofluorimetric approach that is sensitive, simple, validated, and cost-effective has been proposed for the estimation of amlodipine (AML) and perindopril (PER) in their bulk powders, pharmaceutical formulations, and spiked human plasma. The recommended approach utilized the quantitative quenching effect of the two cited drugs on the fluorescence intensity of erythrosine B, as a result of complex binary reactions among each drug with erythrosine B at pH 3.5 (Teorell and Stenhagen buffer). The quenching of erythrosine B fluorescence was recorded at 554 nm after excitation at 527 nm. The calibration curve was detected in the range 0.25–3.0 μg ml⁻¹, with a correlation coefficient of 0.9996 for AML, and 0.1–1.5 μg ml⁻¹, with a correlation coefficient of 0.9996 for PER. The established spectrofluorimetric approach was validated for the estimation of the cited drugs with high sensitivity regarding International Council on Harmonization guidelines. Therefore, the established approach could be utilized for quality control of the cited drugs in their pharmaceutical formulations.